1. Cognate did not fleece, and they are still a unique resource for NWBO.
2. Correct, Cognate and Advent are not NWBO, but they are unique resources for commercial cell manufacturing that NWBO does/may use for making its DCVax platform products.
3. The FDA accepts ECA trials along side other confirmatory data.
4. Admittedly, imo, NWBO and the NIH should have poured far more resources into Flaskworks earlier on, but their manufacturing, intellectual property and validation progress is undeniable.
This has been a long term investment with fudders like yourself clawing at it all the time. It is reassuring it’s on the verge of maa submission.